Differential impact of 5-lipoxygenase-activating protein antagonists on the biosynthesis of leukotrienes and of specialized pro-resolving mediators.
15-lipoxygenase
5-lipoxygenase-activating protein
leukotrienes
lipid mediators
lipoxins
macrophages
metabololipidomics
specialized pro-resolving mediators
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
05
2023
accepted:
08
08
2023
medline:
8
9
2023
pubmed:
8
9
2023
entrez:
8
9
2023
Statut:
epublish
Résumé
Lipoxygenases (LOX) transform arachidonic acid (AA, C20:4) and docosahexaenoic acid (DHA, C22:6) into bioactive lipid mediators (LMs) that comprise not only pro-inflammatory leukotrienes (LTs) but also the specialized pro-resolving mediators (SPMs) that promote inflammation resolution and tissue regeneration. The 5-LOX-activating protein (FLAP) is known to provide AA as a substrate to 5-LOX for generating LTs, such as LTB
Identifiants
pubmed: 37680719
doi: 10.3389/fphar.2023.1219160
pii: 1219160
pmc: PMC10481534
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1219160Informations de copyright
Copyright © 2023 Dahlke, Peltner, Jordan and Werz.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Rep. 2020 Oct 13;33(2):108247
pubmed: 33053344
J Leukoc Biol. 2005 Oct;78(4):871-8
pubmed: 16033810
J Clin Invest. 2017 Aug 1;127(8):3167-3176
pubmed: 28737505
J Med Chem. 2019 May 9;62(9):4312-4324
pubmed: 30869888
J Clin Invest. 2018 Jul 2;128(7):2680-2690
pubmed: 30108195
Biochem Pharmacol. 2021 Nov;193:114759
pubmed: 34487716
Prostaglandins Other Lipid Mediat. 2023 Jun;166:106726
pubmed: 36878381
Nat Commun. 2018 Jan 4;9(1):59
pubmed: 29302056
Biochim Biophys Acta. 2015 Apr;1851(4):377-82
pubmed: 25218301
Immunology. 2022 May;166(1):47-67
pubmed: 35143048
FASEB J. 2015 Dec;29(12):5029-43
pubmed: 26289316
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14530-5
pubmed: 25246560
Eur J Med Chem. 2018 Apr 25;150:876-899
pubmed: 29597170
J Inflamm Res. 2022 Feb 09;15:911-925
pubmed: 35173459
J Lipid Res. 2021;62:100113
pubmed: 34474084
Nature. 2014 Jun 5;510(7503):92-101
pubmed: 24899309
Essays Biochem. 2020 Sep 23;64(3):443-462
pubmed: 32885825
Adv Sci (Weinh). 2023 Feb;10(6):e2205604
pubmed: 36567268
Science. 2007 Jul 27;317(5837):510-2
pubmed: 17600184
Can J Physiol Pharmacol. 1989 May;67(5):456-64
pubmed: 2548691
Eur J Med Chem. 2018 Jun 10;153:34-48
pubmed: 28784429
Biochem Pharmacol. 2022 Oct;204:115210
pubmed: 35973581
Pharmacol Res. 2021 May;167:105556
pubmed: 33812006
FASEB J. 2019 May;33(5):6140-6153
pubmed: 30735438
Biochem Pharmacol. 1993 Jan 7;45(1):101-11
pubmed: 8381000
Br J Pharmacol. 2014 Jun;171(12):3051-64
pubmed: 24641614
Int J Cardiol. 2022 Oct 15;365:34-40
pubmed: 35842004
Clin Chem Lab Med. 1999 Mar;37(3):299-309
pubmed: 10353476
J Clin Invest. 2018 Jul 2;128(7):2657-2669
pubmed: 29757195
Biochim Biophys Acta. 2015 Apr;1851(4):331-9
pubmed: 25152163
Biochem Pharmacol. 2016 Nov 1;119:17-26
pubmed: 27592027
J Biol Chem. 1992 Nov 5;267(31):22048-53
pubmed: 1429555
Eur J Pharmacol. 1994 May 17;267(3):275-80
pubmed: 8088366
Eur J Biochem. 1993 Jul 1;215(1):105-11
pubmed: 8344271
Biochem Pharmacol. 2022 Jan;195:114825
pubmed: 34762841
J Med Chem. 2011 Dec 8;54(23):8013-29
pubmed: 22059882
Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Mar;1867(3):159093
pubmed: 34942381
Trends Pharmacol Sci. 2008 Feb;29(2):72-8
pubmed: 18187210
Expert Opin Ther Pat. 2017 May;27(5):607-620
pubmed: 28005436
Sci Rep. 2017 Aug 24;7(1):9398
pubmed: 28839250
Can J Physiol Pharmacol. 1992 Jun;70(6):799-807
pubmed: 1330258